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Sustained rheumatoid arthritis remission is
uncommon in clinical practice
Femke HM Prince
*, Vivian P Bykerk, Nancy A Shadick, Bing Lu, Jing Cui, Michelle Frits, Christine K Iannaccone,
Michael E Weinblatt and Daniel H Solomon
Abstract
Introduction: Remission is an important goal of therapy in rheumatoid arthritis (RA), but data on duration of
remission are lacking. Our objective was to describe the duration of remission in RA, assessed by different criteria.
Methods: We evaluated patients from the Brigham and Women’s Rheumatoid Arthritis Sequential Study (BRASS)
not in remission at baseline with at least 2 years of follow-up. Remission was assessed according to the Disease
Activity Score 28-C-reactive protein (DAS28-CRP4), Simplified Disease Activity Index (SDAI), and Clinical Disease
Activity Index (CDAI) scores, and the recently proposed American College of Rheumatology (ACR)/European League
against Rheumatism (EULAR) criteria for remission. Analyses were performed by using Kaplan-Meier survival curves.
Results: We identified 871 subjects with ≥2 years of follow-up. Of these subjects, 394 were in remission at one or
more time-points and not in remission at baseline, according to at least one of the following criteria: DAS28-CRP <
2.6 (n = 309), DAS28-CRP < 2.3 (n = 275), SDAI (n = 168), CDAI (n = 170), and 2010 ACR/EULAR (n = 158). The
median age for the 394 subjects at entrance to BRASS was 56 years; median disease duration was 8 years; 81%
were female patients; and 72% were seropositive. Survival analysis performed separately for each remission criterion
demonstrated that < 50% of subjects remained in remission 1 year later. Median remission survival time was 1
year. Kaplan-Meier curves of the various remission criteria did not significantly differ (P = 0.29 according to the log-
rank test).
Conclusions: This study shows that in clinical practice, a minority of RA patients are in sustained remission.
Introduction
Rheumatoid Arthritis (RA) is characterized by joint
inflammation leading to joint destruction. This causes
decreased functional capacity, work disability, and
reduced quality of life [1]. Advances in the understanding
of RA pathogenesis have led to the development of novel
therapeutic targets and new treatment guidelines aiming
for remission [2]. However, it is not generally accepted
how best to define disease remission [3]. At least three
remission definitions are in use: the Disease Activity
Score (DAS)-28 < 2.6 and < 2.3 score, Simplified Disease
Activity Index (SDAI) ≤3.3 score and Clinical Disease
Activity Index (CDAI) ≤2.8 score [4-7]. Recently, the
American College of Rheumatology (ACR), the European
League against Rheumatism (EULAR), and the Outcome
Measures in Rheumatology Initiative (OMERACT) devel-
oped new remission criteria [8,9], the ACR/EULAR pro-
visional definition of remission. All of these remission
definitions examine disease activity at a single point in
time, making them less useful for long-term follow-up
studies [10,11]. Studies evaluating tight control and treat-
to-target strategies advocate that remission should be
r e a c h e da ss o o na sp o s s i b l ea n ds h o u l db em a i n t a i n e d
during the course of the disease [12,13]. The investigators
suggest that remission must be sustained to halt joint
damage [12,13]. Relatively little is known about the dura-
tion of remission in clinical practice. With remission
being a stated goal of RA treatment, it would thus be
important to compare remission criteria and to examine
the duration of RA remission [2].
To understand remission duration in RA, we exam-
ined a large clinical cohort of patients followed up for
multiple years. Our aims were (a) to describe the dura-
tion of remission, regardless of how these patients
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tion according to different remission criteria.
Materials and methods
The Brigham Rheumatoid Arthritis Sequential Study
(BRASS) cohort
BRASS is a prospective, observational, single-center cohort
with RA patients diagnosed by board-certified rheumatolo-
gists at the Brigham and Women’s Hospital Arthritis Cen-
ter [14]. Patients are prospectively monitored, and their RA
is managed according to the preference of the treating
rheumatologist. Patients complete a series of questionnaires
every 6 months, and their rheumatologists carry out an
annual structured physical examination with history, labora-
tory tests to determine RA activity, functional status, and
a d v e r s ee v e n t s .T h es t u d yw a sa p p r o v e db yt h eI n s t i t u t i o n a l
Review Board for Brigham and Women’s Hospital, and all
patients gave written informed consent.
For the Kaplan-Meier analyses, we included only the
394 subjects with (a) at least 2 years follow-up, (b) at
least one remission time-point with subsequently 12
months or more follow-up; and (c) were not in remis-
sion at entrance of BRASS (see Figure 1). The first
remission time point for each patient was considered
baseline (T = 0). Visits included ranged from March
2003 until June 2010.
Remission criteria
The annually collected disease-activity variables were
analyzed, and the proportion of patients in a state of
remission was determined by the following criteria:
DAS28-CRP4 < 2.6 and < 2.3, SDAI ≤3.3, CDAI ≤2.8,
and the ACR/EULAR remission criteria. The remission
criteria are described in detail in Table 1. The DAS28-
CRP4 is based on a 28-joint tender and swollen count,
patient’s global assessment of disease activity, and the
Figure 1 Subject selection, illustrating the study cohort assembly. For the Kaplan-Meier analyses, we include only subjects with at least 2
years of follow-up, at least one remission time-point with subsequently 12 months or more of follow-up, and who were not in remission at
entrance into BRASS. BRASS, Brigham Rheumatoid Arthritis Sequential Study; DAS28-CRP, Disease Activity Score 28-C-reactive protein; ACR,
American College of Rheumatology; SDAI, Simplified Disease Activity Index; CDAI, Clinical Disease Activity; EULAR, European League Against
Rheumatism.
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DAS28-CRP was set at 2.6, equal to the DAS28-ESR.
However, because research has suggested that the cut-
off values to classify remission are lower in DAS28-CRP
compared with the DAS28-ESR, we also evaluated 2.3 as
threshold value [15,16]. The SDAI and CDAI scores use
the same variables as the DAS28-CRP (tender and swol-
len 28-joint count, patient’s global assessment and CRP
in the case of SDAI), but also include the physician’s
global assessment of disease activity [4,7]. The new
ACR/EULAR remission criteria require that tender and
swollen joint count, CRP (milligrams per liter), and
patient’s global assessment (on a 0 to 10 visual analogue
scale) all individually to be ≤ 1 [8].
Statistical analyses
Descriptive statistics were reported as medians (inter-
quartile range, IQR) for continuous variables and as fre-
quencies (percentage) for categoric variables. The
Mann-Whitney U test was used to compare continuous
variables, and the Fisher Exact test for categoric vari-
ables. Patient and disease characteristics of the 224
patients with < 2 years of follow-up and not included in
the study were compared with the 871 patients included
in the study (≥2 years of follow-up).
The primary outcome was time in sustained remission
according to the DAS28-CRP4, SDAI, CDAI, and ACR/
EULAR criteria. The Kaplan-Meier curves and log-rank
test were used to assess the difference of survival func-
tions based on the five remission definitions. We sepa-
rately calculated the number of subjects regaining
remission for the DAS28-CRP < 2.6. Based on prior lit-
erature, we hypothesized that durability of remission
may be different for subjects according to gender, sero-
logic status (seropositive = rheumatoid factor (RF) or
anti-cyclic citrullinated peptide (CCP) positive), and/or
disease duration at start of remission [17-20]. Therefore,
we evaluated subjects in sustained DAS28-CRP < 2.6
remission stratified according to these subgroups. We
decided on a cut-off of 5 years for disease duration,
because 0 to 5 years was the lowest quartile of disease
duration of all patients at their first visit in remission
(median, 11 years; IQR, 5 to 22).
For every RA patient in BRASS, the first time-point in
remission according to one of the remission criteria was
considered the baseline (T = 0) for that specific defini-
tion of remission. To calculate time in remission accord-
ing to that definition, disease activity at consecutive
annual time points was evaluated according to the
remission criteria of that definition. After the subject no
longer met the definition of a given remission criterion
or was censored because of missing data, the data on
the patient thereafter were ignored.
Apart from the survival analyses that censored
patients who did not meeting the definition of remis-
sion, we also calculated the percentage of follow-up
time spent in remission, allowing subjects to regain
remission. For this secondary analysis, in contrary to the
Kaplan-Meier analyses, we included all 871 subjects,
regardless of whether they began BRASS follow-up in
remission.
Nine percent of data on remission-criteria variables
was missing. Multiple imputation by chained equations
was performed to replace missing values in the variables
requested for calculation of remission criteria [21]. Mul-
tiple imputation was applied only if a part of the remis-
sion variables were available; if all data were missing,
the patient was considered lost to follow-up from that
time on.
Outcomes were calculated by using statistical software
SPSS 15.0.1. (SPSS Inc., Chicago, IL, USA) and SAS 9.2.
(SAS Institute Inc., Cary, NC, USA).
Results
Patient and disease characteristics
Of the 1,095 RA patients in BRASS, 871 had at least 2
years of follow-up. Of the 871 subjects with at least 2
years of follow-up, 550 were in remission at one or
more time-points. Of these subjects, 394 had 12 months
of follow-up after their first remission time point and
were not in remission at entrance into BRASS (see
Figure 1). Median follow-up time for the cohort was 5.4
years (IQR, 4.5 to 6.5). Patient and disease characteris-
tics at entrance into the BRASS cohort are given in
Table 2. Patient and disease characteristics at entrance
into BRASS of excluded subjects (< 2 years of follow-
Table 1 Various definitions of remission in RA used in this study
Definition remission Threshold of sum variables
DAS28-CRP4 0.56*√(TJC28) + 0.28*√(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 < 2.6
SDAI TJC28 + SJC28 + CRP + PTglobal + MDglobal ≤3.3
CDAI TJC28 + SJC28 + PTglobal + MDglobal ≤2.8
ACR/EULAR TJC28* ≤1 & SJC28* ≤1 & CRP ≤1 & PTglobal ≤1 ≤4
TJC28, 28 tender-joint count; SJC28, 28 swollen-joint count; CRP, C-reactive protein (mg/L DAS28-CRP4 and mg/dl other definitions); GH, General Health on a 0-
to 100-mm Visual Analogue Scale (VAS); PTglobal, patient’s global assessment on a 0- to 10-cm VAS;
MDglobal, physician’s global assessment on a 0- to 10-cm VAS. *The ACR/EULAR definition prefers the inclusion of feet and ankles for the evaluation of
remission, but use of the 28-joint count is allowed because the overall impact due to reduced joint count was found to be small.
Prince et al. Arthritis Research & Therapy 2012, 14:R68
http://arthritis-research.com/content/14/2/R68
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median age, anti-CCP, and/or RF positivity, median
CRP, morning stiffness, or use of medications. However,
they did differ on gender (77% female; P = 0.049), smok-
ing status (13% smokers; P = 0.029), median disease
duration (7 years P = 0.024); use of MTX (35%; P =
0.001), and biologic DMARDs (28%; P = 0.006).
Durability of sustained remission according to various
remission definitions
The proportion of subjects remaining in remission
according to the different remission criteria is shown in
Figure 2. After 1 year, more than half of the RA patients
previously in remission had fallen out of remission.
Median remission survival, irrespective of the remission
definition, was 1 year. The proportion of subjects con-
sidered to be in remission did not differ according to
different remission criteria (log-rank test, P =0 . 2 9 ) .
Remission using the DAS28-CRP at a 2.6 cut-off was
m e tm o s tf r e q u e n t l y ,a n du s i n gS D A Ia n dt h en e w
ACR/EULAR definition, least frequently.
One-hundred-eighty-two subjects had a median
DAS28-CRP score of 3.8 (median tender-joint count of 6,
swollen joint of 4, CRP of 6.6 mg/L, and general health
on VAS of 25 mm) after they lost DAS28-CRP < 2.6
remission after one annual visit in remission. Of these
182 subjects who were in DAS28-CRP < 2.6 remission at
one visit but not the subsequent annual visit, 41 (23%)
regained remission at the next annual visit. Thirty-six
subjects had a median DAS28-CRP score of 3.7 (median
tender-joint count of 5, swollen joint of 4, CRP of 8.3
mg/L, and general health on VAS of 18 mm) after they
lost DAS28-CRP < 2.6 remission after two subsequent
annual visits in remission. Eleven (31%) of these 36 sub-
jects who were in DAS28-CRP < 2.6 remission at two
subsequent annual visits, but not the subsequent annual
visit, regained remission at the next annual visit.
In Figure 3, the Kaplan-Meier curves are shown for
the 309 subjects in DAS28-CRP < 2.6 remission at ≥1
visit, stratified according to gender (Figure 3a), seroposi-
tivity (Figure 3b), and disease duration (Figure 3c).
Table 2 Patient and disease characteristics at entrance
into BRASS cohort for subjects with ≥2 years of follow-
up, in remission at one or more visit to any remission
definition, and not in remission at entrance
N = 394 n (%)/Median (IQR)
Female 320 (81)
Age (years) 56 (45-63)
Positive anti-CCP or RF status 282 (72)
Smoking 24 (6)
Disease duration (years) 8 (2-19)
Any stiffness 286 (73)
Stiffness duration (minutes) 30-60 (10-90)
CRP (mg/L) 2.7 (1.1-7.9)
NSAIDs 244 (62)
Corticosteroids 103 (26)
MTX 196 (50)
Nonbiologic DMARDs
(not MTX)
137 (35)
Biologics 133 (34)
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARD, disease-
modifying antirheumatic drug; MTX, methotrexate; RF, rheumatoid factor.
 
 
 
 
 
 
 
 
DAS28 <2.6 
 
309  127 / 309 
(41%) 
91 / 127  
(72%) 
37 / 59  
(63%) 
24 / 26  
(92%) 
17 / 18 
(94%) 
8 / 8 
(100%) 
1 / 1 
(100%) 
DAS28 <2.3 
 
275  103 / 275 
(38%) 
62 / 103 
(60%) 
25 / 37 
(68%) 
14 / 19 
(74%) 
10 / 10 
(100%) 
4 / 4 
(100%) 
1 / 1 
(100%) 
SDAI 
 
168  60 / 168 
(36%) 
37 / 60 
(62%) 
17 / 26  
(65%) 
6 / 10 
(60%) 
3 / 3 
(100%) 
1 / 1 
(100%) 
 
CDAI 
 
170  71 / 170 
(42%) 
47 / 71 
(66%) 
17 / 29 
(59%) 
5 / 9 
(56%) 
3 / 3 
(100%) 
1 / 1 
(100%)   
ACR/EULAR 
 
158  55 / 158 
(35%) 
40 / 55 
(73%) 
15 / 26  
(58%) 
6 / 9 
(67%) 
4 / 4 
(100%) 
   
Figure 2 Kaplan-Meier survival curves for subjects maintaining
remission according to various remission definitions,
demonstrating the Kaplan-Meier survival curves for the
percentage of subjects maintaining remission over time. Curves
represent the following remission definitions: blue DAS28-CRP < 2.6
(blue), DAS28-CRP < 2.3 (red), CDAI (green), SDAI (yellow), and 2010
ACR/EULAR (black dotted). Beneath the figure, we include the
number of subjects in remission and the percentage of subjects in
remission compared with the total number of subjects included in
the analysis at each time point. For instance, after 3 years, 37 of 59
patients (63%) were still in remission according to the DAS28-CRP <
2.6. Notice that not 91 but 59 subjects are evaluated at 3 years,
because 32 subjects were censored, as not all patients have same
duration of follow-up (open cohort).
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ease duration maintained remission in the first years of
remission, the survival curves for these subgroups were
not significantly different (log-rank test, P =0 . 4 6b y
gender, log-rank test, P = 0.12 by disease duration).
Kaplan-Meier curves for seropositive and seronegative
subjects were also similar (log-rank test, P = 0.92)
Subjects according to percentage of visits in remission in
BRASS
Considering all 871 subjects in BRASS with ≥2 years of
follow-up, subjects on average spent 31% of their fol-
low-up time in DAS28-CRP < 2.6 remission, 24% in
DAS28-CRP < 2.3 remission, 12% in SDAI remission,
15% in CDAI remission, and 10% in ACR/EULAR
remission. This calculation includes patients who were
never in remission and subjects in remission at entrance
into BRASS.
When we selected the 394 subjects who were in
remission ≥1 visit and were not in remission at entrance
into BRASS, the average time spent in remission was
48%, according to the DAS28-CRP < 2.6, 45% according
to the DAS28-CRP < 2.3, 44% according to the SDAI,
44% according to the CDAI, and 42% according to the
ACR/EULAR. The number of subjects according to
mean time in remission and the various remission cri-
teria are summarized in Table 3.
Discussion
Because of advances made in therapy and treatment
strategies, remission in RA has become the treatment
goal in clinical trials and in clinical practice. However,
previous studies have already suggested that remission
in clinical practice might not be as common as in clin-
ical trials [22,23]. The aim of our study was to evaluate
whether subjects in remission maintain this state over
a long period. Our analyses show that not even half of
the RA patients maintained remission beyond 1 year,
regardless of the remission definition (see Figure 1).
Even after multiple years in remission, a patient’sd i s -
ease can become more active. These findings have clin-
ical implications, in that physicians need to continue to
monitor RA patients in remission closely and may
need to consider treatment changes in these patients if
they flare or present with sustained disease activity.
According to the Kaplan-Meier survival-curve analyses,
the likelihood of patients experiencing active disease
after remission decreases as the years in remission
increase. Whether patients were considered to be in
remission depended on the criteria used, although dif-
ferences in remission duration were not statistically
significant. We found the SDAI and the new ACR/
EULAR criteria to be the most stringent. This is in
accordance with the aims of the ACR, EULAR, and
OMERACT, who requested a stringent remission defi-
n i t i o na n dp r o p o s e dt h eS D A Ia n dn e w l yd e v e l o p e d
ACR/EULAR remission [9]. Although the ACR/EULAR
remission definition was designed and validated for use
in clinical trials and not for observational studies eval-
uating remission in real-life clinical practice, we
thought it would be interesting to evaluate the defini-
tion in the current study [8-11].
A 
 
 
 
 
B 
 
 
 
 
C 
Males 61  28 / 61 
(46%) 
23 / 28  
(82%) 
6 / 13  
(46%) 
4 / 4  
(100%) 
3 / 4 
(75%) 
    
Females 248  99 / 248 
(40%) 
68 / 99 
(69%) 
31 / 46 
(67%) 
20 / 22 
(91%) 
14 / 14 
(100%) 
8 / 8 
(100%) 
1 / 1 
(100%) 
Sero 
positive 
 
229  98 / 229 
(43%) 
67 / 98 
(68%) 
28 / 44 
(64%) 
19 / 21 
(90%) 
13 / 14 
(93%) 
6 / 6 
(100%) 
1 / 1 
(100%) 
Sero 
negative 
 
80  29 / 80 
(36%) 
24 / 29  
(83%) 
9 / 15  
(60%) 
5 / 5  
(100%) 
4 / 4 
(100%) 
2 / 2 
(100%) 
 
≤5 years 
 
97  50 / 97 
(52%) 
36 / 50  
(72%) 
15 / 26  
(58%) 
9 / 10  
(90%) 
5 / 6 
(83%) 
1 / 1 
(100%) 
 
>5 years 
 
212  77 / 212 
(36%) 
55 / 77 
(71%) 
22 / 33 
(67%) 
15 / 16 
(94%) 
12 / 12 
(100%) 
7/ 7 
(100%) 
1 / 1 
(100%) 
Figure 3 Kaplan-Meier survival curves for subjects maintaining DAS28-CRP < 2.6 remission, stratified according to (a) gender, (b)
serologic status, (c) disease duration. We demonstrate the Kaplan-Meier survival curve for the percentage of patients maintaining DAS28-CRP
< 2.6 remission over time. Patients are stratified according to different patient and disease characteristics. Beneath the figure, we include the
number of subjects in remission and the percentage of subjects in remission compared with the total number of subjects included in the
analysis at each time point.
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played a role in not fulfilling remission criteria, because
subjects had a median age of 56 years at entrance to
BRASS. A study from Finland evaluated individuals
from the general population older than 50 years by the
ACR remission criteria and concluded that the majority
did not meet the criteria [24]. However, the aim of the
current study was to evaluate durability of remission,
not the incidence of remission. It is not likely that age
could have played a major role in the fact that more
than half of subjects did not meet remission criteria any
more after only 1 year.
Other studies have described sustained remission in
daily practice as uncommon, being reached by only 17%
to 36% of RA patients for up to 6 months [19,22,25,26].
These studies did not evaluate time in remission beyond
6 months. A recent study investigated the probability of
remaining in remission up to 24 months, according to
the ACR/EULAR, SDAI, and CDAI remission criteria in
two different cohorts [27]. They also concluded that
long-term remission is rare, considering that the prob-
ability of a remission lasting 2 years was 6% to 14%.
We evaluated differences in duration of sustained
remission according to patient and disease characteris-
tics. We did not find statistically significant differences
based on gender, seropositivity, or disease duration, but
these stratified analyses were underpowered and should
be considered only exploratory. A trend seemed to exist
toward longer remission duration in men and subjects
with 5 years or less disease duration at start of remis-
sion. Schipper et al. [19] recently showed that time to
achieve remission correlates with remission duration
[19]. Although our data suggest the same, we cannot be
sure because most BRASS patients enter the study after
the initiation of disease; thus subjects could have been
in remission before entrance into BRASS.
In addition to data on remission duration, we investi-
gated patterns of regaining remission for DAS-CRP <
2.6. Fewer than a quarter of subjects who were pre-
viously in remission at one visit, and then dropped out
of remission, regained remission at the next annual visit.
Slightly more subjects regained remission if demonstrat-
ing remission at two consecutive visits, but the percen-
tage was still low (31%). Subsequently, we evaluated
time spent in remission during the specific follow-up
period for each subject in BRASS with at least 2 years of
follow-up. These data not only show that sustained
remission is uncommon in clinical practice, but also
that most subjects spend little follow-up time in remis-
sion. In the BRASS cohort, most subjects were in remis-
sion during less than half of their follow-up visits.
The ultimate goal of treating RA is to achieve remis-
sion and halt the progression of joint damage. Several
studies show that one time point of meeting remission
Table 3 Number of subjects categorized according to time spent in remission divided by subject-specific follow-up
duration, for each of the remission criteria tested
All subjects in BRASS with ≥2 years of follow-up
Time in remission (%) DAS28-CRP < 2.6
N = 871
a
DAS28-CRP < 2.3
N = 871
a
SDAI
N = 871
a
CDAI
N = 871
a
ACR/EULAR
N = 871
a
0 326 (37%) 401 (46%) 599 (69%) 610 (70%) 634 (73%)
1-25 130 (15%) 146 (17%) 94 (11%) 30 (3%) 87 (10%)
26-50 196 (23%) 163 (19%) 108 (12%) 127 (15%) 101 (12%)
51-75 121 (14%) 102 (12%) 52 (6%) 66 (8%) 39 (4%)
76-99 52 (6%) 30 (3%) 10 (1%) 17 (2%) 7 (1%)
100 46 (5%) 29 (3%) 8 (1%) 21 (2%) 3 (0.3%)
Overall mean time in remission 31% 24% 12% 15% 10%
Selected population of subjects in BRASS
Time in remission (%) DAS28-CRP < 2.6
N = 309
b
DAS28-CRP < 2.3
N = 275
b
SDAI
N = 168
b
CDAI
N = 170
b
ACR/EULAR
N = 158
b
1-25 77 (25%) 89 (32%) 58 (35%) 54 (32%) 60 (38%)
26-50 133 (43%) 111 (40%) 62 (37%) 72 (42%) 64 (41%)
51-75 49 (16%) 37 (13%) 30 (18%) 24 (14%) 18 (11%)
76-99 28 (9%) 21 (8%) 6 (4%) 7 (4%) 8 (5%)
100 22 (7%) 17 (6%) 12 (7%) 13 (8%) 8 (5%)
Overall mean
time in remission
48% 45% 44% 44% 42%
aSubjects in BRASS with ≥2 years of follow-up. Maximum number of visits is eight.
bSubjects in BRASS with ≥2 years of follow-up, one or more visits in remission,
according to the various
definitions; ≥1 year follow-up after first visit in remission and not in remission at entrance into
BRASS. Maximum number of visits is seven (because visit at entrance into BRASS is excluded).
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progress [28-30]. A longer period of meeting the remis-
sion criteria might be an indication of cessation of dis-
ease activity, rather than drug-induced disease
suppression [31]. In juvenile idiopathic arthritis, patients
with inactive disease at two or more yearly visits devel-
oped less cumulative joint damage than did those in
such a state at only one visit [32]. These data suggest
that it is important not only to reach remission, but also
to maintain this state. It will be important to determine
whether RA patients in sustained remission have less
disease destruction compared with those not in sus-
tained remission.
In a recently published study, we showed that an
increased number of visits in remission was associated
with reduced radiographic damage [30]. The goal of the
current study was to describe the duration of remission
with different criteria; we did not examine how patients
achieved remission in this study. This will be the focus
of future work.
The BRASS cohort represents patients from one aca-
demic practice setting, and data are gathered over a
long period. In this single-center cohort, most RA
patients entered the cohort with longstanding disease.
Because disease activity was measured yearly in BRASS,
it is possible that a patient’s disease flared between vis-
its. Thus, this limitation of our data would strengthen
the conclusion that one time point of remission in no
guarantee for sustained remission. Also this will not
affect the comparisons of different remission criteria in
the survival analysis, because all remission criteria were
measured at similar time points.
Conclusion
Recently published recommendations for the manage-
ment of RA by EULAR suggest that as long as a target of
remission or low disease activity has not been reached,
treatment should be adjusted by frequent and strict mon-
itoring [2]. Although remission without respect to dura-
tion is a good goal, it is not the most important target for
therapy. Data from our study confirm that even after
reaching remission, strict monitoring is required, as
fewer than half of the patients in clinical practice will not
sustain remission for more than 1 year.
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